FDA Issues Early Alert for Edwards Lifesciences Commander M Delivery Systems Over Balloon Burst Risk
The US Food and Drug Administration (FDA) has issued an early alert regarding a critical safety issue involving specific lots of Commander M delivery systems, manufactured by Edwards Lifesciences. The devices are used to deliver SAPIEN M3 transcatheter mitral heart valves through blood vessels without open-chest surgery. Edwards Lifesciences has advised affected sites to immediately quarantine and remove the implicated lots from inventory.
The alert follows three reports of delivery system balloons bursting during inflation, leading to one reported death and one serious injury. A burst balloon may cause embolism or prevent the device from being retrieved through the guide sheath, potentially necessitating surgical intervention in patients already considered unsuitable candidates for surgery.
Healthcare facilities are instructed not to use the affected lots (67718561, 67804014, 67887043, and 67887044) and to coordinate with manufacturer representatives to return any recalled inventory. Devices carrying other lot numbers are not affected by this recall and may continue to be used.
Key points
- Edwards Lifesciences has recalled specific lots of Commander M delivery systems used with the SAPIEN M3 transcatheter mitral valve replacement.
- Three reports of balloon rupture during inflation have resulted in one death and one serious injury.
- Potential risks include embolism and device entrapment requiring urgent surgery in high-risk surgical patients.
- Clinicians must stop using and isolate four specific lots: 67718561, 67804014, 67887043, and 67887044.
- Delivery systems bearing other lot numbers remain unaffected and can still be used.
What it means for you
Interventional cardiologists, cardiac catheterisation lab staff, and hospital pharmacists in Pakistan should check catheterisation inventory for the affected lot numbers and quarantine any matching units immediately. Clinicians should consult the Drug Regulatory Authority of Pakistan (DRAP) for local device registration and advisory updates regarding imported transcatheter mitral valve delivery systems. Any suspected adverse incidents should be documented and escalated through institutional and regulatory reporting channels.
Early Alert: Transcatheter Mitral Valve Delivery System Issue from Edwards Lifesciences
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.